Debra Boyer, MD, pediatric pulmonologist at Nationwide Children’s Hospital and co-chair of the American Thoracic Society International Conference Committee says that even though there are strides to be made in pediatric pulmonology, treatments for children with diseases, such as cystic fibrosis, have improved.
Adults and children with cystic fibrosis have seen treatment improvements, despite treatment limitations for other respiratory diseases, says Debra Boyer, MD, pediatric pulmonologist at Nationwide Children’s Hospital and co-chair of the American Thoracic Society International Conference Committee.
Transcript
How have pulmonology treatments for pediatric patients evolved?
Despite what I've said before about some of the limitations, things have evolved tremendously. I think cystic fibrosis (CF) is a prime example. I think all of the work that's been done on the CF modulator therapies; you can't even quantify certainly the emotions that have gone into this, but kids are doing so much better, and adults are now doing so much better with cystic fibrosis because of those early interventions. Similarly, maybe not as giant steps in things like asthma and some of the other conditions that we treat, you've seen some improvements in those as well. But cystic fibrosis is by far the one with the biggest steps that we've seen.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More